Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase NA 1

Status

Completed 8Terminated 2Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 6Observational 2

Sponsor

Cancer Type

Dermatologic 8CNS 6Gastrointestinal 4Other hematologic neoplasm 3Myeloid 3Lymphoid 2Gynecologic 2Breast 2Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Genitourinary 1

Conditions

Carcinoma, Basal Cell 8Skin Neoplasms 2Medulloblastoma 2Neoplasms, Basal Cell 1Eyelid Neoplasms 1Basal Cell Nevus Syndrome 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Completed × sonidegib × Dermatologic × Clear all
NCT04066504 2026-03-18

NISSO

Sun Pharmaceutical Industries Limited

Completed
323 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT03534947 2025-12-16

SONIB

Melanoma Institute Australia

Phase 2 Completed
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

NCT07068568 2025-07-16

BCC-Sonidegib

Federico II University

Completed
12 enrolled
Dermatologic

Carcinoma, Basal Cell, Eyelid Neoplasms, Neoplasms, Basal Cell

NCT00880308 2020-12-19

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
103 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma

NCT01208831 2020-12-19

An East Asian Study of LDE225

Novartis

Phase 1 Completed
45 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma

NCT01327053 2019-08-28

BOLT

Novartis

Phase 2 Completed
230 enrolled 26 charts
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

NCT01529450 2017-01-16

Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

Stanford University

Phase NA Completed
11 enrolled 10 charts
Dermatologic

Carcinoma, Basal Cell

NCT01350115 2015-10-19

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Novartis

Phase 2 Completed
10 enrolled 9 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡